Acute Myeloid Leukemia (AML)

AML BACKGROUND

• AML is a cancer of the blood and bone marrow which can progress rapidly if left untreated 
• 60-70% of AML patients initially respond to chemotherapy, however AML is characterized by a high degree of relapse
• Patients with FLT3-ITD mutations (20-30% of cases) have a higher chance of relapse
• Overall, AML 5-year survival rate is only ~30%

UNMET NEED

• Novel and more effective treatments are needed for the treatment of AML 
• JNTX-104 has the potential for accelerated approval